| 1. |
Tennant, R. and Wiggers, C. J. (1935) The effect of coronary occlusion on myocardial contraction. Am. J. Physiol.
112, 351–361.
|
| |
| 2. |
Curtis, M. J. (1998) Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced
ventricular fibrillation. Cardiovasc. Res.
39, 194–215.
|
| |
| 3. |
Campbell, R. W. (1983) Treatment and prophylaxis of ventricular arrhythmias in acute myocardial infarction. Am. J. Cardiol.
52, 55C–59C.
|
| |
| 4. |
Curtis, M. J., Pugsley, M. K., and Walker, M. J. (1993) Endogenous chemical mediators of ventricular arrhythmias in ischaemic
heart disease. Cardiovasc. Res.
27, 703–719.
|
| |
| 5. |
Harris, A. S., Bisteni, A., Russell, R. A., Brigham, J. C., and Firestone, J. E. (1954) Excitatory factors in ventricular
tachycardia resulting from myocardial ischaemia. Potassium as a major excitant. Science
119, 200–203.
|
| |
| 6. |
Harris, A. S., Toth, L. A., and Hooey, T. E. (1958) Arrhythmic and antiarrhythmic effects of sodium, potassium, and calcium
salts and of glucose injected into coronary arteries of infarcted and normal hearts. Circ. Res.
6, 570–579.
|
| |
| 7. |
Hearse, D. J., Humphrey, S. M., Feuvray, D., and De Leiris, J. (1976) A biochemical and ultrastructural study of the species
variation in myocardial cell damage. J. Mol. Cell Cardiol.
8, 759–778.
|
| |
| 8. |
Antman, E. M., Lau, J., Kupelnick, B., Mosteller, F., and Chalmers, T. C. (1992) A comparison of results of meta-analyses
of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA
268, 240–248.
|
| |
| 9. |
Curtis, M. J. and Hearse, D. J. (1989) Ischaemia-induced and reperfusion-induced arrhythmias differ in their sensitivity to
potassium: Implications for mechanisms of initiation and maintenance of ventricular fibrillation. J. Mol. Cell Cardiol.
21, 21–40.
|
| |
| 10. |
Morena, H., Janse, M. J., Fiolet, J. W., Krieger, W. J., Crijns, H., and Durrer, D. (1980) Comparison of the effects of regional
ischemia, hypoxia, hyperkalemia, and acidosis on intracellular and extracellular potentials and metabolism in the isolated
porcine heart. Circ. Res.
46, 634–646.
|
| |
| 11. |
Dennis, J. and Moore, R. M. (1938) K+ changes in the functioning heart under conditions of ischaemia and congestion. Am. J. Physiol.
123, 579–593.
|
| |
| 12. |
Hill, J. L. and Gettes, L. S. (1980) Effect of acute coronary artery occlusion on local myocardial extracellular K+ activity in swine. Circulation
61, 768–778.
|
| |
| 13. |
Hirche, H., Franz, C., Bos, L., Bissig, R., Lang, R., and Schramm, M. (1980) Myocardial extracellular K+ and H+ increase and noradrenaline release as possible cause of early arrhythmias following acute coronary artery occlusion in pigs.
J. Mol. Cell Cardiol.
12, 579–593.
|
| |
| 14. |
Curtis, M. J. (1991) The rabbit dual coronary perfusion model: A new method for assessing the pathological relevance of individual
products of the ischaemic milieu: role of potassium in arrhythmogenesis. Cardiovasc. Res.
25, 1010–1022.
|
| |
| 15. |
Janse, M. J. and Kleber, A. G. (1981) Electrophysiological changes and ventricular arrhythmias in the early phase of regional
myocardial ischemia. Circ. Res.
49, 1069–1081.
|
| |
| 16. |
Schmidt, F. O. and Erlanger, J. (1928) Directional differences in the conduction of the impulse through heart muscle and their
possible relation to extrasystolic and fibrillatory contractions. Am. J. Physiol.
87, 326–347.
|
| |
| 17. |
Ettinger, P. O., Regan, T. J., Oldewurtel, H. A., and Khan, M. I. (1973) Ventricular conduction delay and arrhythmias during
regional hyperkalemia in the dog. Electrical and myocardial ion alterations. Circ. Res.
33, 521–531.
|
| |
| 18. |
Pelleg, A., Mitamura, H., Price, R., Kaplinsky, E., Menduke, H., Dreifus, L. S., and Michelson, E. L. (1989) Extracellular
potassium ion dynamics and ventricular arrhythmias in the canine heart. J. Am. Coll. Cardiol.
13, 941–950.
|
| |
| 19. |
Black, J. W., Duncan, W. A., and Shanks, R. G. (1965) Comparison of some properties of pronethalol and propranolol. Br. J. Pharmacol.
25, 577–591.
|
| |
| 20. |
Curtis, M. J., Botting, J. H., Hearse, D. J., and Walker, M. J. A. (1989) The sympathetic nervous system, catecholamines and
ischaemia-induced arrhythmias: dependence upon serum potassium concentration, in Adrenergic System and Ventricular Arrhythmias in Myocardial Infarction (Brachmann, J. and Schömig, A., eds.), Springer-Verlag, Berlin, pp. 206–219.
|
| |
| 21. |
Priori, S. and Schwartz, P. J. (1989) Catecholamine-dependent cardiac arrhythmias: mechanisms and implication, in Adrenergic System and Ventricular Arrhythmias in Myocardial Infarction (Brachmann, J. and Schömig, A., eds.), Springer-Verlag, Berlin, pp. 239–247.
|
| |
| 22. |
Sheridan, D. J., Penkoske, P. A., Sobel, B. E., and Corr, P. B. (1980) Alpha adrenergic contributions to dysrhythmia during
myocardial ischemia and reperfusion in cats. J. Clin. Invest.
65, 161–171.
|
| |
| 23. |
Sheridan, D. J. and Culling, W. (1985) Electrophysiological effects of alpha-adrenoceptor stimulation in normal and ischemic
myocardium. J. Cardiovasc. Pharmacol.
7, S55–S60.
|
| |
| 24. |
Culling, W., Penny, W. J., Lewis, M. J., Middleton, K. and Sheridan, D. J. (1984) Effects of myocardial catecholamine depletion
on cellular electrophysiology and arrhythmias during ischaemia and reperfusion. Cardiovasc. Res.
18, 675–682.
|
| |
| 25. |
Bolli, R., Fisher, D. J., Taylor, A. A., Young, J. B., and Miller, R. R. (1984) Effect of alpha-adrenergic blockade on arrhythmias
induced by acute myocardial ischemia and reperfusion in the dog. J. Mol. Cell Cardiol.
16, 1101–1117.
|
| |
| 26. |
Tosaki, A., Szekeres, L., and Hearse, D. J. (1987) Metoprolol reduces reperfusion-induced fibrillation in the isolated rat
heart: Protection is secondary to bradycardia. J. Cardiovasc. Pharmacol.
10, 489–497.
|
| |
| 27. |
Daugherty, A., Frayn, K. N., Redfern, W. S., and Woodward, B. (1986) The role of cat-echolamines in the production of ischaemia-induced
ventricular arrhythmias in the rat in vivo and in vitro. Br. J. Pharmacol.
87, 265–277.
|
| |
| 28. |
Botting, J. H., Johnston, K. M., Macleod, B. A., and Walker, M. J. (1983) The effect of modification of sympathetic activity
on responses to ligation of a coronary artery in the conscious rat. Br. J. Pharmacol.
79, 265–271.
|
| |
| 29. |
Cinca, J., Bardaji, A., and Salas-Caudevilla, A. (1989) Ventricular arrhythmias and local electrograms after chronic regional
denervation of the ischemic area in the pig heart. J. Am. Coll. Cardiol.
14, 225–232.
|
| |
| 30. |
Schomig, A., Dart, A. M., Dietz, R., Mayer, E., and Kubler, W. (1984) Release of endogenous catecholamines in the ischemic
myocardium of the rat. Part A: Locally mediated release. Circ. Res.
55, 689–701.
|
| |
| 31. |
Lameris, T. W., de Zeeuw, S., Alberts, G., Boomsma, F., Duncker, D. J., Verdouw, P. D., et al. (2000) Time course and mechanism
of myocardial catecholamine release during transient ischemia in vivo. Circulation
101, 2645–2650.
|
| |
| 32. |
Clements-Jewery, H., Hearse, D. J., and Curtis, M. J. (2002) Independent contribution of catecholamines to arrhythmogenesis
during evolving infarction in the isolated rat heart. Br. J. Pharmacol.
135, 807–815.
|
| |
| 33. |
Rochette, L., Didier, J. P., Moreau, D., Bralet, J., and Opie, L. H. (1984) Role of beta-adrenoreceptor antagonism in the
prevention of reperfusion ventricular arrhythmias: Effects of acebutolol, atenolol, and d-propranolol on isolated working
rat hearts subject to myocardial ischemia and reperfusion. Am. Heart J.
107, 1132–1141.
|
| |
| 34. |
Altschuld, R. A. and Billman, G. E. (2000) Beta2-Adrenoceptors and ventricular fibrillation. Pharmacol. Ther.
88, 1–14.
|
| |
| 35. |
Billman, G. E., Castillo, L. C., Hensley, J., Hohl, C. M., and Altschuld, R. A. (1997) Beta2-adrenergic receptor antagonists
protect against ventricular fibrillation: In vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation
in animals susceptible to sudden death. Circulation
96, 1914–1922.
|
| |
| 36. |
Paletta, M. J., Abraham, S., Beatch, G. N., and Walker, M. J. (1989) Mechanisms underlying the antiarrhythmic properties of
beta-adrenoceptor blockade against ischaemia-induced arrhythmias in acutely prepared rats. Br. J. Pharmacol.
98, 87–94.
|
| |
| 37. |
Dai, S. and Ogle, C. W. (1990) Ventricular histamine concentrations and mast cell counts in the rat heart during acute ischaemia.
Agents Actions
29, 138–143.
|
| |
| 38. |
Mannaioni, P. F. (1985) Physiology and pharmacology of cardiac histamine, revisited in: Fontiers in Histamine Research (Ganellin, C. R. and Schwartz, J. C., eds.), J Wright London, pp. 236–297.
|
| |
| 39. |
Ryan, M. J. and Brody, M. J. (1970) Distribution of histamine in the canine autonomic nervous system. J. Pharmacol. Exp. Ther.
174, 123–132.
|
| |
| 40. |
Harvey, S. C. (1978) Studies on myocardial histamine. Effects of catecholamine-depleting drugs. Arch. Int. Pharmacodyn. Ther.
232, 141–149.
|
| |
| 41. |
Anrep, G. V., Barsoum, G. S., and Talaat, M. (1936) Liberation of histamine by the heart muscle. J. Physiol.
86, 431–451.
|
| |
| 42. |
Cerbai, E., Amerini, S., and Mugelli, A. (1990) Histamine and abnormal automaticity in barium-and strophanthidin-treated sheep
Purkinje fibers. Agents Actions
31, 1–10.
|
| |
| 43. |
Wolff, A. A. and Levi, R. (1986) Histamine and cardiac arrhythmias. Circ. Res.
58, 1–16.
|
| |
| 44. |
Cameron, J. S., Swigart, C. R., Shin, G. S., Katz, D., and Bassett, A. L. (1990) Enhanced susceptibility to histamine-induced
cardiac arrhythmias in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol.
15, 626–632.
|
| |
| 45. |
Gettes, L. S. and Cascio, W. E. (1992) Effects of acute ischaemia on cardiac electrophysiology, in The Heart and Cardiovascular System, 2nd Ed. (Fozzard, H. A., Haber, E., Jennings, R. B., Katz, A. M., and Morgan, H. E., eds.), Raven Press, New York, pp. 2021–2054.
|
| |
| 46. |
Harris, A. S. (1950) Delayed development of ventricular ectopic rhythms following experimental coronary occlusion. Circulation
1, 1318–1328.
|
| |
| 47. |
Podzuweit, T. (1982) Early arrhythmias resulting from acute myocardial ischaemia: Possible role of cyclic AMP, in Early Arrhythmias Resulting from Myocardial Ischaemia (Parratt, J. R., ed.), McMillan, Basingstoke, UK, pp. 171–198..
|
| |
| 48. |
Rochette, L., Yao-Kouame, J., Bralet, J., and Opie, L. H. (1988) Effects of promethazine on ischemic and reperfusion arrhythmias
in rat heart. Fund. Clin. Pharmacol.
2, 385–397.
|
| |
| 49. |
Dai, S. (1987) Ventricular histamine concentrations and arrhythmias during acute myocardial ischaemia in rats. Agents Actions
21, 66–71.
|
| |
| 50. |
Dai, S. (1984) Effects of SKandF 93479 on experimentally induced ventricular arrhythmias in dogs, rats and mice. Agents Actions
15, 131–136.
|
| |
| 51. |
Banning, M. M. and Curtis, M. J. (1995) Protection by cimetidine, but not ranitidine, implies that H2 receptors do not mediate
arrhythmogenesis in a rat model of regional ischaemia and reperfusion in vitro. Cardiovasc. Res.
30, 705–710.
|
| |
| 52. |
Wolff, A. A., Levi, R., Chenouda, A. A., and Fisher, V. J. (1984) Ventricular arrhythmias parallel cardiac histamine release
after coronary artery occlusion in the dog: effects of ranitidine. Circulation
70(Suppl II), 225.
|
| |
| 53. |
Imamura, M., Lander, H. M., and Levi, R. (1996) Activation of histamine H3-receptors inhibits carrier-mediated norepinephrine
release during protracted myocardial ischemia. Comparison with adenosine A1-receptors and alpha2-adrenoceptors. Circ. Res.
78, 475–481.
|
| |
| 54. |
Levi, R. and Smith, N. C. (2000) Histamine H3-receptors: A new frontier in myocardial ischemia. J. Pharmacol. Exp. Ther.
292, 825–830.
|
| |
| 55. |
Berkowitz, B. A., Lee, C. H., and Spector, S. (1974) Disposition of serotonin in the rat blood vessels and heart. Clin. Exp. Pharmacol. Physiol.
1, 397–400.
|
| |
| 56. |
Sole, M. J., Shum, A., and Van Loon, G. R. (1979) Serotonin metabolism in the normal and failing hamster heart. Circ. Res.
45, 629–634.
|
| |
| 57. |
Kaumann, A. J. (1983) A classification of heart serotonin receptors. Naunyn Schmiedebergs Arch. Pharmacol.
322(Suppl), R42.
|
| |
| 58. |
Bach, T., Syversveen, T., Kvingedal, A. M., Krobert, K. A., Brattelid, T., Kaumann, A. J., and Levy, F. O. (2001) 5HT4(a)
and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch. Pharmacol.
363, 146–160.
|
| |
| 59. |
Saxena, P. R. and Villalon, C. M. (1991) 5-Hydroxytryptamine: A chameleon in the heart. Trends Pharmacol. Sci.
12, 223–227.
|
| |
| 60. |
Richardson, B. P., Engel, G., Donatsch, P., and Stadler, P. A. (1985) Identification of serotonin M-receptor subtypes and
their specific blockade by a new class of drugs. Nature
316, 126–131.
|
| |
| 61. |
Thandroyen, F. T., Saman, S., and Opie, L. H. (1985) Serotonin and the heart: Pharmacological evaluation with the S2-serotonergic
antagonist ketanserin, in Serotonin and the Cardiovascular System (Vanhoutte, P. M., ed.), Raven Press, New York, pp. 87–93.
|
| |
| 62. |
Coker, S. J. (1986) Does ketanserin reduce ischaemia and reperfusion-induced arrhythmias in anaesthetised rats? Br. J. Pharmacol.
88, 288P.
|
| |
| 63. |
Shaw, L. A. and Coker, S. J. (1996) Suppression of reperfusion-induced arrhythmias with combined administration of 5-HT2 and
thromboxane A2 antagonists. Br. J. Pharmacol.
117, 817–822.
|
| |
| 64. |
Coker, S. J. and Ellis, A. M. (1987) Ketanserin and ritanserin can reduce reperfusion-induced but not ischaemia-induced arrhythmias
in anaesthetised rats. J. Cardiovasc. Pharmacol.
10, 479–484.
|
| |
| 65. |
Saman, S., Thandroyen, F. and Opie, L. H. (1985) Serotonin and the heart: Effects of ketanserin on myocardial function, heart
rate, and arrhythmias. J. Cardiovasc. Pharmacol.
7, S70–S75.
|
| |
| 66. |
Williams, F. M., Rothaul, A. L., Kane, K. A., and Parratt, J. R. (1985) Antiarrhythmic and electrophysiological effects of
ICS 205-930, an antagonist of 5-hydroxytryptamine at peripheral receptors. J. Cardiovasc. Pharmacol.
7, 550–555.
|
| |
| 67. |
Coker, S. J., Dean, H. G., Kane, K. A., and Parratt, J. R. (1986) The effects of ICS 205–930, a 5-HT antagonist, on arrhythmias
and catecholamine release during canine myocardial ischaemia and reperfusion. Eur. J. Pharmacol.
127, 211–218.
|
| |
| 68. |
Nearing, B. D., Hutter, J. J., and Verrier, R. L. (1996) Potent antifibrillatory effect of combined blockade of calcium channels
and 5-HT2 receptors with nexopamil during myocardial ischemia and reperfusion in dogs: Comparison to diltiazem. J. Cardiovasc. Pharmacol.
27, 777–787.
|
| |
| 69. |
Corr, P. B., Creer, M. H., Yamada, K. A., Saffitz, J. E., and Sobel, B. E. (1989) Prophylaxis of early ventricular fibrillation
by inhibition of acylcarnitine accumulation. J. Clin. Invest.
83, 927–936.
|
| |
| 70. |
Waldo, A. L., Camm, A. J., deRuyter, H., Freidman, P. L., MacNeil, D. J., Pitt, B., et al. (1995) Survival with oral d-sotalol
in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial).
Am. J. Cardiol.
75, 1023–1027.
|
| |
| 71. |
CAST. (1989) Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression
after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med.
321, 406–412.
|
| |
| 72. |
Corr, P. B., Gross, R. W., and Sobel, B. E. (1984) Amphipathic metabolites and membrane dysfunction in ischemic myocardium.
Circ. Res.
55, 135–154.
|
| |
| 73. |
Corr, P. B., Yamada, K. A., Creer, M. H., Sharma, A. D., and Sobel, B. E. (1987) Lysophosphoglycerides and ventricular fibrillation
early after onset of ischemia. J. Mol. Cell Cardiol.
19(Suppl 5), 45–53.
|
| |
| 74. |
Corr, P. B. and Yamada, K. A. (1995) Selected metabolic alterations in the ischemic heart and their contributions to arrhythmogenesis.
Herz
20, 156–168.
|
| |
| 75. |
Kiyosue, T. and Arita, M. (1986) Effects of lysophosphatidylcholine on resting potassium conductance of isolated guinea pig
ventricular cells. Pflugers Arch.
406, 296–302.
|
| |
| 76. |
Nakaya, H., Kimura, S., and Kanno, M. (1984) Suppression of lysophosphatidylcholine-induced abnormal automaticity by verapamil
in canine Purkinje fibers. Jpn. J. Pharmacol.
36, 371–378.
|
| |
| 77. |
Duan, J. and Moffat, M. P. (1991) Protective effects of d,l-carnitine against arrhythmias induced by lysophosphatidylcholine
or reperfusion. Eur. J. Pharmacol.
192, 355–363.
|
| |
| 78. |
van der Vusse, G. J., Prinzen, F. W., van Bilsen, M., Engels, W., and Reneman, R. S. (1987) Accumulation of lipids and lipid-intermediates
in the heart during ischaemia. Basic Res. Cardiol.
82, 157–167.
|
| |
| 79. |
Sakata, K., Hayashi, H., Kobayashi, A., and Yamazaki, N. (1989) Mechanism of arrhythmias induced by palmitylcarnitine in guinea
pig papillary muscle. Cardiovasc. Res.
23, 505–511.
|
| |
| 80. |
Yokota, S., Hironaka, Y., and Ohara, N. (1989) Effects of 1-carnitine on membrane potential derangements induced by palmitoylcarnitine
and anoxia in isolated superfused guinea-pig papillary muscle. Res. Commun. Chem. Pathol. Pharmacol. 66, 179–190.
|
| |
| 81. |
Meszaros, J. and Pappano, A. J. (1988) Single cell model for 1-palmitoylcarnitine-induced ventricular arrhythmias. Circulation
78(Suppl II), 569.
|
| |
| 82. |
Matsui, K., Nakazawa, M., Takeda, K., and Imai, S. (1985) Effect of 1-carnitine chloride and its acetyl derivative on the
electrophysiological derangement induced by palmityl-l-carnitine in isolated canine ventricular muscle. Jpn. J. Pharmacol.
39, 263–270.
|
| |
| 83. |
Busselen, P., Sercu, D., and Verdonck, F. (1988) Exogenous palmitoyl carnitine and membrane damage in rat hearts. J. Mol. Cell Cardiol.
20, 905–916.
|
| |
| 84. |
Hearse, D. J. (1990) Ischemia, reperfusion, and the determinants of tissue injury. Cardiovasc. Drugs Ther.
4(Suppl 4), 767–776.
|
| |
| 85. |
Montrucchio, G., Alloatti, G., and Camussi, G. (2000) Role of platelet-activating factor in cardiovascular pathophysiology.
Physiol. Rev.
80, 1669–1699.
|
| |
| 86. |
Montrucchio, G., Camussi, G., Tetta, C., Emanuelli, G., Orzan, F., Libero, L., and Brusca, A. (1986) Intravascular release
of platelet-activating factor during atrial pacing. Lancet
2, 293.
|
| |
| 87. |
Annable, C. R., McManus, L. M., Carey, K. D., and Pinckard, R. N. (1985) Isolation of platelet activating factor (PAF) from
ischaemic baboon myocardium. Fed. Proc.
44, 1271.
|
| |
| 88. |
Sybertz, E. J., Watkins, R. W., Baum, T., Pula, K., and Rivelli, M. (1985) Cardiac, coronary and peripheral vascular effects
of acetyl glyceryl ether phosphoryl choline in the anesthetized dog. J. Pharmacol. Exp. Ther.
232, 156–162.
|
| |
| 89. |
Pugsley, M. K., Salari, H., and Walker, M. J. (1991) Actions of platelet-activating factor on isolated rat hearts. Circ. Shock
35, 207–214.
|
| |
| 90. |
Koltai, M., Tosaki, A., Hosford, D., Esanu, A., and Braquet, P. (1991) Effect of BN 50739, a new platelet activating factor
antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts. Cardiovasc. Res.
25, 391–397.
|
| |
| 91. |
Baker, K. E. and Curtis, M. J. (1999) Protection against ventricular fibrillation by the PAF antagonist, BN-50739, involves
an ischaemia-selective mechanism. J. Cardiovasc. Pharmacol.
34, 394–401.
|
| |
| 92. |
Stahl, G. L., Terashita, Z., and Lefer, A. M. (1988) Role of platelet activating factor in propagation of cardiac damage during
myocardial ischemia. J. Pharmacol. Exp. Ther.
244, 898–904.
|
| |
| 93. |
Auchampach, J. A., Muruyama, M., Cavero, I., and Gross, G. J. (1991) Blocking platelet activating factor receptors with RP59227
decreases myocardial infarct size and the incidence of ventricular fibrillation. J. Mol. Cell. Cardiol.
23(Suppl 3), S52.
|
| |
| 94. |
Auchampach, J. A., Pieper, G. M., Cavero, I., and Gross, G. J. (1998) Effect of the platelet-activating factor antagonist
RP 59227 (Tulopafant) on myocardial ischemia/ reperfusion injury and neutrophil function. Basic Res. Cardiol.
93, 361–371.
|
| |
| 95. |
Sariahmetoglu, M., Cakici, I., and Kanzik, I. (1998) Effects of WEB 2086 on the protective role of preconditioning against
arrhythmias in rats. Pharmacol. Res.
38, 173–178.
|
| |
| 96. |
Tamura, K., Kimura, Y., Tamura, T., Kitashiro, S., Izuoka, T., Tsuji, H., et al. (1994) The effect of platelet-activating-factor
antagonist TCV-309 on arrhythmias and functional recovery during myocardial reperfusion. Coron. Artery Dis.
5, 267–273.
|
| |
| 97. |
Qayumi, A. K., English, J. C., Godin, D. V., Ansley, D. M., Loucks, E. B., Lee, J. U., and Kim, C. W. (1998) The role of platelet-activating
factor in regional myocardial ischemia-reperfusion injury. Ann. Thorac. Surg.
65, 1690–1697.
|
| |
| 98. |
Tamargo, J., Delgado, C., Diez, J., and Delpon, E. (1988) Cardiac electrophysiology of PAF-acether antagonists, in Ginkgolides, Chemistry, Biology, Pharmacology and Clinical Perspectives (Braquet, P., ed.), Vol. 1, J. R. Prous SciencePubl., Barcelona, pp. 417–431.
|
| |
| 99. |
Karmazyn, M. and Dhalla, N. S. (1983) Physiological and pathophysiological aspects of cardiac prostaglandins. Can. J. Physiol. Pharmacol.
61, 1207–1225.
|
| |
| 100. |
Hsueh, W. and Needleman, P. (1978) Sites of lipase activation and prostaglandin synthesis in isolated perfused rabbit hearts
and hydronephrotic kidneys. Prostaglandins
16, 661–681.
|
| |
| 101. |
Bolton, H. S., Chanderbhan, R., Bryant, R. W., Bailey, J. M., Weglicki, W. B., and Vahouny, G. V. (1980) Prostaglandin synthesis
by adult heart myocytes. J. Mol. Cell Cardiol.
12, 1287–1298.
|
| |
| 102. |
Karmazyn, M. (1989) Synthesis and relevance of cardiac eicosanoids with particular emphasis on ischemia and reperfusion. Can. J. Physiol. Pharmacol. 67, 912–921.
|
| |
| 103. |
De Deckere, E. A., Nugteren, D. H., and Ten Hoor, F. (1977) Prostacyclin is the major prostaglandin released from the isolated
perfused rabbit and rat heart. Nature
268, 160–163.
|
| |
| 104. |
Parratt, J. (1993) Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc. Res.
27, 693–702.
|
| |
| 105. |
Mest, H. J., Schror, K., and Forster, W. (1972) Antiarrhythmic properties of PGE2. Adv. Biosci.
9, 395–400.
|
| |
| 106. |
Mest, H. J., Mentz, P. and Forster, W. (1974) Effects of prostaglandins on experimental arrhythmias. Pol. J. Pharmacol. Pharm.
26, 151–156.
|
| |
| 107. |
Au, T. L., Collins, G. A., Harvie, C. J., and Walker, M. J. (1979) The actions of prostaglandins I2 and E2 on arrhythmias
produced by coronary occlusion in the rat and dog. Prostaglandins
18, 707–720.
|
| |
| 108. |
Hohlfeld, T., Meyer-Kirchrath, J., Vogel, Y. C., and Schror, K. (2000) Reduction of infarct size by selective stimulation
of prostaglandin EP3 receptors in the reperfused ischemic pig heart. J. Mol. Cell Cardiol.
32, 285–296.
|
| |
| 109. |
Dix, R. K., Kelliher, G. J., Jurkiewicz, N., and Smith, J. B. (1982) Effect of sulfinpyrazone on ventricular arrhythmia, prostaglandin
synthesis, and catecholamine release following coronary artery occlusion in the cat. J. Cardiovasc. Pharmacol.
4, 1068–1076.
|
| |
| 110. |
Fagbemi, S. O. (1984) The effect of aspirin, indomethacin and sodium meclofenamate on coronary artery ligation arrhythmias
in anaesthetized rats. Eur. J. Pharmacol.
97, 283–287.
|
| |
| 111. |
Coker, S. J., Parratt, J. R., Ledingham, I. M., and Zeitlin, I. J. (1981) Thromboxane and prostacyclin release from ischaemic
myocardium in relation to arrhythmias. Nature
291, 323–324.
|
| |
| 112. |
Coker, S. J. and Parratt, J. R. (1985) AH23848, a thromboxane antagonist, suppresses ischemia and reperfusion-induced arrhythmias
in anaesthetized greyhounds. Br. J. Pharmacol.
86, 259–264.
|
| |
| 113. |
Hamberg, M., Svensson, J., and Samuelsson, B. (1975) Thromboxanes: A new group of biologically active compounds derived from
prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA
72, 2994–2998.
|
| |
| 114. |
Ellis, E. F., Oelz, O., Roberts, L. J., II, Payne, N. A., Sweetman, B. J., Nies, A. S., et al. (1976) Coronary arterial smooth
muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science
193, 1135–1137.
|
| |
| 115. |
Parratt, J. R. and Wainwright, C. L. (1986) Ventricular arrhythmias induced by local injections of vasoconstrictors following
coronary occlusion. Br. J. Pharmacol.
88, 397P.
|
| |
| 116. |
Coker, S. J. (1984) Further evidence that thromboxane exacerbates arrhythmias: Effects of UK38485 during coronary artery occlusion
and reperfusion in anaesthetized greyhounds. J. Mol. Cell Cardiol.
16, 633–641.
|
| |
| 117. |
O’Connor, K. M., Friehling, T. D., and Kowey, P. R. (1989) The effect of thromboxane inhibition on vulnerability to ventricular
fibrillation in the acute and chronic feline infarction models. Am. Heart J.
117, 848–853.
|
| |
| 118. |
Ezeamuzie, I. C. and Assem, E. S. (1983) Effects of leukotrienes C4 and D4 on guinea-pig heart and the participation of SRS-A
in the manifestations of guinea-pig cardiac anaphylaxis. Agents Actions
13, 182–187.
|
| |
| 119. |
Letts, L. G. and Piper, P. J. (1982) The actions of leukotrienes C4 and D4 on guinea-pig isolated hearts. Br. J. Pharmacol.
76, 169–176.
|
| |
| 120. |
Burke, J. A., Levi, R., Guo, Z. G., and Corey, E. J. (1982) Leukotrienes C4, D4 and E4: Effects on human and guinea-pig cardiac
preparations in vitro. J. Pharmacol. Exp. Ther.
221, 235–241.
|
| |
| 121. |
Roth, D. M. and Lefer, A. M. (1983) Studies on the mechanism of leukotriene induced coronary artery constriction. Prostaglandins
26, 573–581.
|
| |
| 122. |
Mayer, M. (1988) Leukotrienes and other lipoxygenase metabolites of arachidonic acid: their role in edema, ischemia and demyelination
of the central nervous system. Acta Univ. Palacki Olomuc Fac. Med.
119, 181–186.
|
| |
| 123. |
Terashita, Z. I., Fukui, H., Hirata, M., Terao, S., Ohkawa, S., Nishikawa, K., and Kikuchi, S. (1981) Coronary vasoconstriction
and PGI2 release by leukotrienes in isolated guinea pig hearts. Eur. J. Pharmacol.
73, 357–361.
|
| |
| 124. |
Beatch, G. N., Courtice, I. D., and Salari, H. (1989) A comparative study of the antiar-rhythmic properties of eicosanoid
inhibitors, free radical scavengers and potassium channel blockers on reperfusion induced arrhythmias in the rat. Proc. West Pharmacol. Soc.
32, 285–289.
|
| |
| 125. |
Hahn, R. A., MacDonald, B. R., Simpson, P. J., Potts, B. D., and Parli, C. J. (1990) Antagonism of leukotriene B4 receptors
does not limit canine myocardial infarct size. J. Pharmacol. Exp. Ther.
253, 58–66.
|
| |
| 126. |
Rastegar, M. A., Marchini, F., Morazzoni, G., Vegh, A., Papp, J. G., and Parratt, J. R. (2000) The effects of Z13752A, a combined
ACE/NEP inhibitor, on responses to coronary artery occlusion; A primary protective role for bradykinin. Br. J. Pharmacol.
129, 671–680.
|
| |
| 127. |
Rochette, L., Ribuot, C., Belichard, P., Bril, A., and Devissaguet, M. (1987) Protective effect of angiotensin converting
enzyme inhibitors (CEI): Captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischemia
and reperfusion in rat. Clin. Exp. Hypertens. A
9, 365–368.
|
| |
| 128. |
Ribuot, C. and Rochette, L. (1987) Converting enzyme inhibitors (captopril, enalapril, perindopril) prevent early-post infarction
ventricular fibrillation in the anaesthetized rat. Cardiovasc. Drugs. Ther.
1, 51–55.
|
| |
| 129. |
Shimada, Y. and Avkiran, M. (1996) Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting
enzyme/kininase II in the ischemic zone: Mediated by endogenous bradykinin? J. Cardiovasc. Pharmacol.
27, 428–438.
|
| |
| 130. |
De Mello, W. and Altieri, P. (1992) The role of the renin-angiotensin system in the control of cell communication in the heart:
Effects of enalapril and angiotensin II. J. Cardiovasc. Pharmacol.
20, 643–651.
|
| |
| 131. |
De Mello, W. C. and Crespo, M. J. (1999) Correlation between changes in morphology, electrical properties, and angiotensin-converting
enzyme activity in the failing heart. Eur. J. Pharmacol.
378, 187–194.
|
| |
| 132. |
Scholkens, B. A., Linz, W., Lindpainter, K., and Ganten, D. (1987) Angiotensin deteriorates but bradykinin improves cardiac
function following ischaemia in isolated rat hearts. J. Hypertens.
5(Suppl 5), S7–S9.
|
| |
| 133. |
Hiura, N., Wakatsuki, T., Yamamoto, T., Nishikado, A., Oki, T., and Ito, S. (2001) Effects of angiotensin II type 1 receptor
antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion.
J. Cardiovasc. Pharmacol.
38, 729–736.
|
| |
| 134. |
Harada, K., Komuro, I., Hayashi, D., Sugaya, T., Murakami, K., and Yazaki, Y. (1998) Angiotensin II type 1a receptor is involved
in the occurrence of reperfusion arrhythmias. Circulation
97, 315–317.
|
| |
| 135. |
Modesti, P. A., Vanni, S., Paniccia, R., Bandinelli, B., Bertolozzi, I., Polidori, G., et al. (1999) Characterization of endothelin-1
receptor subtypes in isolated human cardiomyocytes. J. Cardiovasc. Pharmacol.
34, 333–339.
|
| |
| 136. |
Miyauchi, T., Yanagisawa, M., Tomizawa, T., Sugishita, Y., Suzuki, N., Fujino, M., et al. (1989) Increased plasma concentrations
of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet
2, 53–54.
|
| |
| 137. |
Ezra, D., Goldstein, R. E., Czaja, J. F., and Feuerstein, G. Z. (1989) Lethal ischemia due to intracoronary endothelin in
pigs. Am. J. Physiol.
257, H339–H343.
|
| |
| 138. |
Underwood, D. C., Falotico, R., Cheung, W.-M., and Tobia, A. J. (1989) Dissociation of coronary vasoconstrictor and arrhythmogenic
properties of endothelin in the dog. Circulation
80(Suppl II), 149.
|
| |
| 139. |
Salvati, P., Chierchia, S., Dho, L., Ferrario, R. G., Parenti, P., Vicedomini, G., et al. (1991) Proarrhythmic activity of
intracoronary endothelin in dogs: Relation to the site of administration and to changes in regional flow. J. Cardiovasc. Pharmacol.
17, 1007–1014.
|
| |
| 140. |
Toth, M., Solti, F., Merkely, B., Kekesi, V., Horkay, F., Szokodi, I., et al. (1995) Ventricular tachycardias induced by intracoronary
administration of endothelin-1 in dogs. J. Cardiovasc. Pharmacol.
26(Suppl 3), S153–S155.
|
| |
| 141. |
Horkay, F., Geller, L., Kiss, O., Szabo, T., Vago, H., Kekesi, V., et al. (2000) Bosentan the mixed endothelin-A-and-B-receptor
antagonist suppresses intrapericardial endothelin-1-induced ventricular arrhythmias. J. Cardiovasc. Pharmacol.
36, S320–S322.
|
| |
| 142. |
Kiss, O., Geller, L., Merkely, B., Szabo, T., Raschack, M., Seres, L., et al. (2000) Endothelin-A-receptor antagonist LU 135.252
inhibits the formation of ventricular arrhythmias caused by intrapericardial infusion of endothelin-1. J. Cardiovasc. Pharmacol.
36, S317–S319.
|
| |
| 143. |
Merkely, B., Szabo, T., Geller, L., Kiss, O., Horkay, F., Raschack, M., et al. (2000) The selective endothelin-A-receptor
antagonist LU 135.252 inhibits the direct arrhythmogenic action of endothelin-1. J. Cardiovasc. Pharmacol.
36, S314–S316.
|
| |
| 144. |
Douglas, S. A., Nichols, A. J., Feuerstein, G. Z., Elliott, J. D., and Ohlstein, E. H. (1998) SB 209670 inhibits the arrhythmogenic
actions of endothelin-1 in the anesthetized dog. J. Cardiovasc. Pharmacol.
31(Suppl 1), S99–S102.
|
| |
| 145. |
Geller, L., Merkely, B., Szokodi, I., Szabo, T., Vecsey, T., Juhasz-Nagy, A., et al. (1998) Electrophysiological effects of
intrapericardial infusion of endothelin-1. Pacing Clin. Electrophysiol.
21, 151–156.
|
| |
| 146. |
Yorikane, R., Shiga, H., Miyake, S., and Koike, H. (1990) Evidence for direct arrhythmogenic action of endothelin. Biochem. Biophys. Res. Commun.
173, 457–462.
|
| |
| 147. |
Kim, D. (1991) Endothelin activation of an inwardly rectifying K+ current in atrial cells. Circ. Res.
69, 250–255.
|
| |
| 148. |
Raschack, M., Juchelka, F., and Rozek-Schaefer, G. (1998) The endothelin-A antagonist LU 135 252 supresses ischemic ventricular
extrasystoles and fibrillation in pigs and prevents hypoxic cellular decoupling. J. Cardiovasc. Pharmacol.
31(Suppl 1), S145–S148.
|
| |
| 149. |
Sharif, I., Kane, K. A., and Wainwright, C. L. (1998) Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic?
Cardiovasc. Res.
39, 625–32.
|
| |
| 150. |
Crockett, T. R., Sharif, I., Kane, K. A., and Wainwright, C. L. (2000) Sarafotoxin 6c protects against ischaemia-induced cardiac
arrhythmias in vivo and in vitro in the rat. J. Cardiovasc. Pharmacol.
36, S297–S299.
|
| |
| 151. |
Crockett, T. R., Scott, G. A., McGowan, N. W., Kane, K. A., and Wainwright, C. L. (2001) Anti-arrhythmic and electrophysiological
effects of the endothelin receptor antagonists, BQ-123 and PD161721. Eur. J. Pharmacol.
432, 71–77.
|
| |
| 152. |
Sharif, I., Crockett, T. R., Kane, K. A., and Wainwright, C. L. (2001) The effects of endothelin-1 on ischaemia-induced ventricular
arrhythmias in rat isolated hearts. Eur. J. Pharmacol.
427, 235–242.
|
| |
| 153. |
Lee, A. Y. (1990) Endogenous opioid peptides and cardiac arrhythmias. Int. J. Cardiol.
27, 145–151.
|
| |
| 154. |
Jin, W. Q., Tai, K. K., Chan, T. K., and Wong, T. M. (1995) Further characterization of [3H]U69593 binding sites in the rat
heart. J. Mol. Cell. Cardiol.
27, 1507–1511.
|
| |
| 155. |
Zimlichman, R., Gefel, D., Eliahou, H., Matas, Z., Rosen, B., Gass, S., et al. (1996) Expression of opioid receptors during
heart ontogeny in normotensive and hypertensive rats. Circulation
93, 1020–1025.
|
| |
| 156. |
Krumins, S. A., Faden, A. I., and Feuerstein, G. (1985) Opiate binding in rat hearts: Modulation of binding after hemorrhagic
shock. Biochem. Biophys. Res. Commun.
127, 120–128.
|
| |
| 157. |
Ventura, C., Bastagli, L., Bernardi, P., Caldarera, C. M., and Guarnieri, C. (1989) Opioid receptors in rat cardiac sarcolemma:
Effect of phenylephrine and isoproterenol. Biochim. Biophys. Acta
987, 69–74.
|
| |
| 158. |
Fryer, R. M., Hsu, A. K., Nagase, H., and Gross, G. J. (2000) Opioid-induced cardioprotection against myocardial infarction
and arrhythmias: Mitochondrial versus sarcolemmal ATP-sensitive potassium channels. J. Pharmacol. Exp. Ther.
294, 451–457.
|
| |
| 159. |
Sitsapesan, R. and Parratt, J. R. (1989) The effects of drugs interacting with opioid receptors on the early ventricular arrhythmias
arising from myocardial ischaemia. Br. J. Pharmacol.
97, 795–800.
|
| |
| 160. |
Wong, T. M., Lee, A. Y., and Tai, K. K. (1990) Effects of drugs interacting with opioid receptors during normal perfusion
or ischemia and reperfusion in the isolated rat heart—an attempt to identify cardiac opioid receptor subtype(s) involved in
arrhythmogenesis. J. Mol. Cell Cardiol.
22, 1167–1175.
|
| |
| 161. |
Pugsley, M. K., Penz, W. P., Walker, M. J., and Wong, T. M. (1992) Cardiovascular actions of the kappa-agonist, U-50,488H,
in the absence and presence of opioid receptor blockade. Br. J. Pharmacol.
105, 521–526.
|
| |
| 162. |
Fagbemi, O., Kane, K. A., Lepran, I., Parratt, J. R., and Szekeres, L. (1983) Antiarrhythmic actions of meptazinol, a partial
agonist at opiate receptors, in acute myocardial ischemia. Br. J. Pharmacol.
78, 455–460.
|
| |
| 163. |
Fagbemi, O., Lepran, I., Parratt, J. R., and Szekeres, L. (1982) Naloxone inhibits early arrhythmias resulting from acute
coronary ligation. Br. J. Pharmacol.
76, 504–506.
|
| |
| 164. |
Pugsley, M. K. (2002) The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system.
Pharmacol. Ther.
93, 51–75.
|
| |
| 165. |
Boachie-Ansah, G., Sitsapesan, R., Kane, K. A., and Parratt, J. R. (1989) The antiarrhythmic and cardiac electrophysiological
effects of buprenorphine. Br. J. Pharmacol.
97, 801–808.
|
| |
| 166. |
Sarne, Y., Flitstein, A., and Oppenheimer, E. (1991) Anti-arrhythmic activities of opioid agonists and antagonists and their
stereoisomers. Br. J. Pharmacol.
102, 696–698.
|
| |
| 167. |
Pugsley, M. K., Saint, D. A., Penz, M. P., and Walker, M. J. (1993) Electrophysiological and antiarrhythmic actions of the
kappa agonist PD 129290, and its R,R (+)-enantiomer, PD 129289. Br. J. Pharmacol.
110, 1579–1585.
|
| |
| 168. |
Pruett, J. K., Blair, J. R., and Adams, R. J. (1991) Cellular and subcellular actions of opioids in the heart, in Opioids in Anaesthesia (Estafonous, F. G., ed.), Vol. II, Butterworth-Heinmann, Boston, MA, pp. 61–70.
|
| |
| 169. |
Lahti, R. A., VonVoigtlander, P. F., and Barsuhn, C. (1982) Properties of a selective kappa agonist, U-50,488H. Life Sci.
31, 2257–2260.
|
| |
| 170. |
Lee, A. Y., Chen, Y. T., Kan, M. N., P’Eng F. K., Chai, C. Y., and Kuo, J. S. (1992) Consequences of opiate agonist and antagonist
in myocardial ischaemia suggest a role of endogenous opioid peptides in ischaemic heart disease. Cardiovasc. Res.
26, 392–395.
|
| |
| 171. |
Yu, X., Zhang, W., Bian, J., and Wong, T. M. (1999) Pro-and anti-arrhythmic effects of a kappa opioid receptor agonist: A
model for the biphasic action of a local hormone in the heart. Clin. Exp. Pharmacol. Physiol.
26, 842–844.
|
| |
| 172. |
Pugsley, M. K., Penz, W. P., Walker, M. J., and Wong, T. M. (1992) Antiarrhythmic effects of U-50,488H in rats subject to
coronary artery occlusion. Eur. J. Pharmacol.
212, 15–19.
|
| |
| 173. |
Garlick, P. B., Radda, G. K., and Seeley, P. J. (1979) Studies of acidosis in the ischaemic heart by phosphorus nuclear magnetic
resonance. Biochem. J.
184, 547–554.
|
| |
| 174. |
Smith, W. T., Fleet, W. F., Johnson, T. A., Engle, C. L., and Cascio, W. E. (1995) The Ib phase of ventricular arrhythmias
in ischemic in situ porcine heart is related to changes in cell-to-cell electrical coupling. Experimental Cardiology Group,
University of North Carolina. Circulation
92, 3051–3060.
|
| |
| 175. |
Yan, G. X. and Kleber, A. G. (1992) Changes in extracellular and intracellular pH in ischemic rabbit papillary muscle. Circ. Res.
71, 460–470.
|
| |
| 176. |
Lagadic-Gossmann, D., Buckler, K. J., and Vaughan-Jones, R. D. (1992) Role of bicarbonate in pH recovery from intracellular
acidosis in the guinea-pig ventricular myocyte. J. Physiol.
458, 361–384.
|
| |
| 177. |
Avkiran, M. (2001) Protection of the ischaemic myocardium by Na+/H+ exchange inhibitors: Potential mechanisms of action. Basic Res. Cardiol.
96, 306–311.
|
| |
| 178. |
Scholz, W., Albus, U., Counillon, L., Gogelein, H., Lang, H. J., Linz, W., et al. (1995) Protective effects of HOE642, a selective
sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc. Res.
29, 260–268.
|
| |
| 179. |
Aye, N. N., Komori, S., and Hashimoto, K. (1999) Effects and interaction, of cariporide and preconditioning on cardiac arrhythmias
and infarction in rat in vivo. Br. J. Pharmacol.
127, 1048–1055.
|
| |
| 180. |
Wu, D., Stassen, J. M., Seidler, R., and Doods, H. (2000) Effects of BIIB513 on ischemia-induced arrhythmias and myocardial
infarction in anesthetized rats. Basic Res. Cardiol.
95, 449–456.
|
| |
| 181. |
Lorrain, J., Briand, V., Favennec, E., Duval, N., Grosset, A., Janiak, P., et al. (2000) Pharmacological profile of SL 59.1227,
a novel inhibitor of the sodium/hydrogen exchanger. Br. J. Pharmacol.
131, 1188–1194.
|
| |
| 182. |
Hartmann, M. and Decking, U. K. (1999) Blocking Na+/H+ exchange by cariporide reduces Na+-overload in ischemia and is cardioprotective.
J. Mol. Cell Cardiol.
31, 1985–1995.
|
| |
| 183. |
Stromer, H., de Groot, M. C., Horn, M., Faul, C., Leupold, A., Morgan, J. P., et al. (2000) Na+/H+ exchange inhibition with
HOE642 improves postischemic recovery due to attenuation of Ca2+ overload and prolonged acidosis on reperfusion. Circulation
101, 2749–2755.
|
| |
| 184. |
Portman, M. A., Panos, A. L., Xiao, Y., Anderson, D. L., and Ning, X. (2001) HOE-642 (cariporide) alters pHi and diastolic
function after ischemia during reperfusion in pig hearts in situ. Am. J. Physiol. Heart Circ. Physiol.
280, H830–H834.
|
| |
| 185. |
Ibuki, C., Hearse, D. J., and Avkiran, M. (1993) Mechanisms of antifibrillatory effect of acidic reperfusion: Role of perfusate
bicarbonate concentration. Am. J. Physiol.
264, H783–H790.
|
| |
| 186. |
Coughlin, S. R. (2000) Thrombin signalling and protease-activated receptors. Nature
407, 258–264.
|
| |
| 187. |
Sabri, A., Muske, G., Zhang, H., Pak, E., Darrow, A., Andrade-Gordon, P., et al. (2000) Signaling properties and functions
of two distinct cardiomyocyte protease-activated receptors. Circ. Res.
86, 1054–1061.
|
| |
| 188. |
Steinberg, S. F., Robinson, R. B., Lieberman, H. B., Stern, D. M., and Rosen, M. R. (1991) Thrombin modulates phosphoinositide
metabolism, cytosolic calcium, and impulse initiation in the heart. Circ. Res.
68, 1216–1229.
|
| |
| 189. |
Yan, G. X., Park, T. H., and Corr, P. B. (1995) Activation of thrombin receptor increases intracellular Na+ during myocardial
ischemia. Am. J. Physiol.
268, H1740–H1748.
|
| |
| 190. |
Anderson, K. E., Dart, A. M., and Woodcock, E. A. (1995) Inositol phosphate release and metabolism during myocardial ischemia
and reperfusion in rat heart. Circ. Res.
76, 261–268.
|
| |
| 191. |
Jacobsen, A. N., Du, X. J., Lambert, K. A., Dart, A. M., and Woodcock, E. A. (1996) Arrhythmogenic action of thrombin during
myocardial reperfusion via release of inositol 1,4,5-triphosphate. Circulation
93, 23–26.
|
| |
| 192. |
Janse, M. J. (1992) Reentrant arrhythmias, in The Heart and Cardiovascular System (Fozzard, H. A., Haber, E., Jennings, R. B., Katz, A. M., and Morgan, H. E., eds.), Raven Press, New York, pp. 2055–2094.
|
| |
| 193. |
Parratt, J. R. (1982) Early Arrhythmias Resulting from Acute Myocardial Ischaemia, Macmillan, Basingstoke, UK.
|
| |
| 194. |
Lab, M. J. (1982) Contraction-excitation feedback in myocardium. Physiological basis and clinical relevance. Circ. Res.
50, 757–766.
|
| |